News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
782,411 Results
Type
Article (53472)
Company Profile (353)
Press Release (728569)
Multimedia
Podcasts (167)
Webinars (25)
Section
Business (219769)
Career Advice (2637)
Deals (38180)
Drug Delivery (142)
Drug Development (85870)
Employer Resources (183)
FDA (17391)
Job Trends (16170)
News (371923)
Policy (35927)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2807)
Academic (1)
Accelerated approval (38)
Adcomms (28)
Allergies (163)
Alliances (54309)
ALS (189)
Alzheimer's disease (1746)
Antibody-drug conjugate (ADC) (362)
Approvals (17644)
Artificial intelligence (648)
Autoimmune disease (186)
Automation (46)
Bankruptcy (380)
Best Places to Work (12127)
BIOSECURE Act (22)
Biosimilars (205)
Biotechnology (215)
Bladder cancer (170)
Brain cancer (65)
Breast cancer (680)
Cancer (5235)
Cardiovascular disease (456)
Career advice (2242)
Career pathing (43)
CAR-T (305)
CDC (59)
Celiac Disease (2)
Cell therapy (829)
Cervical cancer (40)
Clinical research (73205)
Collaboration (1925)
Company closure (6)
Compensation (1222)
Complete response letters (74)
COVID-19 (2908)
CRISPR (109)
C-suite (950)
Cystic fibrosis (155)
Data (6662)
Decentralized trials (2)
Denatured (55)
Depression (153)
Diabetes (536)
Diagnostics (7032)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (316)
Drug pricing (221)
Drug shortages (33)
Duchenne muscular dystrophy (247)
Earnings (95525)
Editorial (69)
Employer branding (23)
Employer resources (163)
Events (126242)
Executive appointments (1052)
FDA (20714)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (25)
Funding (1603)
Gene editing (225)
Generative AI (64)
Gene therapy (683)
GLP-1 (1101)
Government (5112)
Grass and pollen (8)
Guidances (387)
Healthcare (19909)
HIV (71)
Huntington's disease (53)
IgA nephropathy (89)
Immunology and inflammation (285)
Immuno-oncology (71)
Indications (135)
Infectious disease (3202)
Inflammatory bowel disease (212)
Inflation Reduction Act (16)
Influenza (128)
Intellectual property (265)
Interviews (456)
IPO (17163)
IRA (60)
Job creations (4392)
Job search strategy (1854)
JPM (73)
Kidney cancer (18)
Labor market (91)
Layoffs (611)
Leadership (40)
Legal (9029)
Liver cancer (97)
Longevity (21)
Lung cancer (696)
Lymphoma (395)
Machine learning (47)
Management (63)
Manufacturing (904)
MASH (180)
Medical device (14367)
Medtech (14433)
Mergers & acquisitions (22153)
Metabolic disorders (1412)
mRNA (183)
Multiple sclerosis (177)
NASH (19)
Neurodegenerative disease (368)
Neuropsychiatric disorders (103)
Neuroscience (3131)
Neurotech (1)
NextGen: Class of 2026 (7050)
Non-profit (4844)
Now hiring (69)
Obesity (681)
Opinion (329)
Ovarian cancer (176)
Pain (231)
Pancreatic cancer (249)
Parkinson's disease (310)
Partnered (37)
Patents (541)
Patient recruitment (549)
Peanut (64)
People (63174)
Pharmaceutical (94)
Pharmacy benefit managers (34)
Phase 1 (22683)
Phase 2 (32029)
Phase 3 (24161)
Pipeline (6172)
Policy (334)
Postmarket research (2902)
Preclinical (9802)
Press Release (69)
Prostate cancer (269)
Psychedelics (54)
Radiopharmaceuticals (310)
Rare diseases (977)
Real estate (6632)
Recruiting (75)
Regulatory (26626)
Reports (55)
Research institute (2577)
Resumes & cover letters (427)
Rett syndrome (30)
RNA editing (20)
RSV (84)
Schizophrenia (163)
Series A (274)
Series B (202)
Service/supplier (13)
Sickle cell disease (108)
Special edition (28)
Spinal muscular atrophy (165)
Sponsored (46)
Startups (3935)
State (2)
Stomach cancer (20)
Supply chain (116)
Tariffs (99)
The Weekly (110)
Vaccines (1115)
Venture capital (98)
Weight loss (450)
Women's health (103)
Worklife (20)
Date
Today (164)
Last 7 days (751)
Last 30 days (3207)
Last 365 days (31604)
2026 (5860)
2025 (32011)
2024 (36753)
2023 (41380)
2022 (52638)
2021 (57362)
2020 (56111)
2019 (49172)
2018 (37253)
2017 (34552)
2016 (34578)
2015 (40531)
2014 (34794)
2013 (30322)
2012 (32189)
2011 (32632)
2010 (31076)
Location
Africa (952)
Alabama (89)
Alaska (7)
Arizona (330)
Arkansas (15)
Asia (45119)
Australia (7375)
California (11994)
Canada (3446)
China (1213)
Colorado (509)
Connecticut (522)
Delaware (353)
Europe (99212)
Florida (1791)
Georgia (382)
Hawaii (3)
Idaho (64)
Illinois (961)
India (78)
Indiana (563)
Iowa (23)
Japan (469)
Kansas (129)
Kentucky (44)
Louisiana (35)
Maine (76)
Maryland (1475)
Massachusetts (8734)
Michigan (355)
Minnesota (656)
Mississippi (6)
Missouri (137)
Montana (33)
Nebraska (30)
Nevada (133)
New Hampshire (86)
New Jersey (3226)
New Mexico (31)
New York (3163)
North Carolina (1585)
North Dakota (9)
Northern California (5865)
Ohio (361)
Oklahoma (23)
Oregon (47)
Pennsylvania (2411)
Puerto Rico (24)
Rhode Island (50)
South America (1339)
South Carolina (70)
South Dakota (1)
Southern California (4686)
Tennessee (192)
Texas (1858)
United States (42836)
Utah (360)
Vermont (1)
Virginia (300)
Washington D.C. (84)
Washington State (965)
West Virginia (4)
Wisconsin (121)
Wyoming (2)
782,411 Results for "aragon pharmaceuticals inc acquired by johnson and johnson".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results - March 2, 2026
March 3, 2026
·
1 min read
Press Releases
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
March 3, 2026
·
10 min read
Press Releases
CraniUS Therapeutics Appoints Johnson & Johnson Senior Executive, Oray Boston Jr. to Board of Directors
February 18, 2026
·
2 min read
Press Releases
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
February 9, 2026
·
10 min read
Press Releases
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
February 26, 2026
·
11 min read
Press Releases
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
February 25, 2026
·
13 min read
Press Releases
Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference
February 10, 2026
·
1 min read
Press Releases
Johnson & Johnson reports Q4 and Full-Year 2025 results
January 21, 2026
·
20 min read
Press Releases
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
February 18, 2026
·
6 min read
Press Releases
Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
February 3, 2026
·
1 min read
1 of 78,242
Next
